- Recruiting
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma
Updated: May 23, 2022
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma

Denosumab for Smoldering Multiple Myeloma
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.
Sponsor
University of Rochester
Collaborator
Amgen
Location
New York
ClinicalTrials.gov Identifier: NCT03839459
Official Title: Denosumab for Smoldering Multiple Myeloma
First Posted : February 15, 2019
https://clinicaltrials.gov/ct2/show/NCT03839459
Drug: Denosumab
Denosumab: National Cancer Institute
Location
United States, New York